|
Delayed
Sao Paulo
22:45:44 05/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 46.65 BRL | -5.47% |
|
-9.51% | -14.01% |
| 11:19pm | European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading | MT |
| 10-02 | Major drugmakers turn to China for licensing deals | RE |
| Market Cap | 71.3B 470B 94.27B 84.1B 78.35B 134B 9,079B 135B 947B 368B 4,634B 354B 346B 14,895B | P/E 2026 * |
13.8x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 92.54B 610B 122B 109B 102B 174B 11,783B 176B 1,229B 478B 6,014B 459B 449B 19,331B | EV / Sales 2026 * |
2.73x | EV / Sales 2027 * | 2.53x |
| Free-Float |
92.75% | Yield 2026 * |
3.9% | Yield 2027 * | 4.2% |
Last Transcript: GSK plc
| 1 day | -5.47% | ||
| 1 week | -9.51% | ||
| Current month | -6.98% | ||
| 1 month | -6.33% | ||
| 3 months | -14.93% | ||
| 6 months | -19.35% | ||
| Current year | -14.01% |
| 1 week | 46.35 |  | 51.55 |
| 1 month | 46.35 | | 52.41 |
| Current year | 46.35 | | 63.24 |
| 1 year | 46.35 | | 63.24 |
| 3 years | 33.33 | | 63.24 |
| 5 years | 30.69 | | 63.24 |
| 10 years | 30.69 | | 63.24 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.47% | -9.51% | - | - | 94.34B | |
| +0.87% | -2.74% | +36.36% | +112.80% | 1,019B | |
| -0.83% | -6.43% | +35.23% | +61.93% | 617B | |
| +0.25% | -1.13% | +14.38% | +78.56% | 464B | |
| -2.93% | -5.89% | +57.58% | +35.07% | 356B | |
| +0.93% | -1.83% | +20.98% | +41.43% | 333B | |
| +0.12% | -4.05% | +10.09% | +33.53% | 267B | |
| -0.89% | -5.83% | -7.56% | +7.91% | 244B | |
| -0.14% | -3.92% | +36.60% | +51.56% | 218B | |
| -0.34% | -5.26% | +26.97% | +93.05% | 179B | |
| Average | -0.92% | -3.54% | +25.62% | +57.31% | 410.8B | |
| Weighted average by Cap. | -0.34% | -3.54% | +28.83% | +68.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.91B 224B 44.84B 40B 37.27B 63.86B 4,318B 64.34B 450B 175B 2,204B 168B 165B 7,084B | 35.49B 234B 46.92B 41.85B 38.99B 66.83B 4,518B 67.32B 471B 183B 2,306B 176B 172B 7,413B |
| Net income | 5.19B 34.22B 6.86B 6.12B 5.7B 9.77B 661B 9.84B 68.89B 26.8B 337B 25.75B 25.19B 1,084B | 6.2B 40.93B 8.2B 7.32B 6.82B 11.68B 790B 11.77B 82.39B 32.05B 403B 30.8B 30.13B 1,296B |
| Net Debt | 21.24B 140B 28.08B 25.05B 23.33B 39.99B 2,704B 40.29B 282B 110B 1,380B 105B 103B 4,436B | 18.53B 122B 24.5B 21.85B 20.36B 34.89B 2,359B 35.15B 246B 95.71B 1,204B 91.96B 89.97B 3,870B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/10/26 | R$46.65 | -5.47% | 54 |
| 02/10/26 | R$49.35 | -1.60% | 2 |
| 30/09/26 | R$50.15 | -2.72% | 18 |
| 29/09/26 | R$51.55 | +0.90% | 1 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- G1SK34 Stock
Select your edition
All financial news and data tailored to specific country editions
